Achieve Life Sciences (ACHV) announced new data showing that 6 and 12 weeks of cytisinicline delivers meaningful quitting success, regardless of participants’ prior use of smoking cessation medications or number of previous quit attempts. Achieve also announces late-breaking survey data from ORCA-OL, demonstrating participant experience with extended cytisinicline use. These findings will be presented during the Society for Research on Nicotine & Tobacco 2026 Annual Meeting, March 4-7 in Baltimore, Maryland.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV: